EVGN — Evogene Ltd.

Evogene Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2026, Evogene reported consolidated cash and equivalents of approximately $13.1 million.
• Revenue: Q1 2026 revenues were approximately $0.3 million, a significant decline from $2.3 million in Q1 2025, primarily due to lower seed sales.
• Operating Loss: The operating loss increased to approximately $3.2 million compared to $3 million in the same period last year.
• Net Loss: The net loss for Q1 2026 was approximately $5.9 million, up from $3 million in Q1 2025, attributed to decreased revenues and increased financing expenses.
• R&D Expenses: R&D expenses decreased to approximately $1.8 million from $2.5 million in Q1 2025.

2. Strategic Updates and Business Highlights

• Focus on Core Technology: Evogene is concentrating its efforts on its proprietary Campus AI engine, emphasizing technological collaborations, including a partnership with Google to enhance drug discovery capabilities.
• Pharmaceutical Collaborations: The company announced three new collaborations in the pharmaceutical sector, targeting high unmet medical needs in areas such as inflammatory bowel disease and demyelinating disorders.
• Agricultural Developments: Evogene's subsidiary, AgPlenus, is advancing its fungicide development program and has terminated a collaboration with Bayer due to target biology issues but is exploring future partnerships.

3. Forward Guidance and Outlook

• Evogene anticipates continued progress across its three core areas: technology, pharmaceuticals, and agriculture, with a focus on establishing strategic collaborations and advancing its product pipeline.
• The company is optimistic about the potential for new strategic deals in both the agricultural and pharmaceutical sectors, although significant transactions may take time to materialize.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The dramatic drop in revenue raises concerns about the company's current market position and sales performance.
• Increased Losses: The increase in net losses and operating losses indicates financial strain and may affect investor confidence.
• Collaboration Termination: The termination of the collaboration with Bayer reflects potential challenges in the agricultural segment, which could hinder growth prospects.
• Market Risks: The geopolitical situation in Israel and its impact on operations could pose risks to future performance.

5. Notable Q&A Insights

• Management indicated that while they are in discussions with potential strategic partners, including large pharmaceutical companies, significant equity investments may take time to secure.
• The CEO expressed confidence in the company's direction and the interdependence of success across its agricultural, pharmaceutical, and technology segments, suggesting that advancements in one area could bolster opportunities in others.

Overall, while Evogene is making strides in its strategic initiatives and collaborations, the financial metrics indicate challenges that need to be addressed to ensure sustainable growth and investor confidence.